Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: Human cytochromes mediating transformation and cytochrome inhibitory effects

Psychopharmacology

Volumn 140, Issue 3, 1998, Pages 293-299

  Von Moltke, L L ^a   Greenblatt, D J ^a   Grassi, J M ^a   Granda, B W ^a   Fogelman, S M ^a   Harmatz, J S ^a   Kramer, S J ^b   Fabre, L F ^b   Shader, R I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fabre Kramer Pharmaceuticals   (United States)

Author keywords

1 (2 Pyrimidinyl) piperazine; Cytochromes P450; Gepirone

Indexed keywords

1 (2 PYRIMIDINYL)PIPERAZINE; GEPIRONE; PIPERAZINE DERIVATIVE;

ARTICLE; BIOTRANSFORMATION; DEPRESSION; DRUG BIOAVAILABILITY; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; BIOTRANSFORMATION; BUSPIRONE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; MICROSOMES, LIVER; PYRIMIDINES;

EID: 0031775639     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050770     Document Type: Article

References (24)

1. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokin 32:210-258
2. Court MH, von Moltke LL, Shader RT Greenblatt DJ (1997) Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 18:213-226
3. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235
4. Feiger AD (1996) A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 35:659-665
5. Fulton B, Brogden RN (1997) Buspirone: an updated version of its clinical pharmacology and therapeutic applications. CNS Drugs 7:68-88
6. Greenblatt DJ, von Moltke LL (1997) Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes. In: Hori W (ed) Drug-drug interactions: analyzing in vitro-in-vivo correlations. International Business Communications, Southboro, Mass., 2.2.1-2.2.28
7. 14C-labeled gepirone to rats. Bristol-Myers, Scientific Report HO-JC-25354
8. Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ (1997) Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 62:348-354
9. McGrath PJ, Stewart JW, Quitkin FM, Wager S, Jenkins SW, Archibald DG, Stringfellow JC, Robinson DS (1994) Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 5:347-352
10. Robinson DS, Shrotriya RC, Alms DR, Messina M, Andary J (1989) Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone. Psychopharmacol Bull 25: 21-23
11. Schmider J, Greenbaltt DJ, von Moltke LL, Harmatz JS, Duan SX, Karsov D, Shader RI (1996) Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology 52:125-134
12. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI (1997a) Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6, 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 18:227-240
13. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI (1997b) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin parahydroxylation. Br J Clin Pharmacol 44:495-498
14. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423
15. 14C-gepirone in humans following intravenous and oral administration. Bristol-Myers, Scientific Report TAY-LK-21405
16. Tay LK, Dixon JF, Sostrin MB, Barr WH, Farmen RH, Pittman KA (1992) The site of gastrointestinal absorption of gepirone in humans. J Clin Pharmacol 32:827-832
17. Tay LK, Sciacca MA, Sostrin MB, Farmen RH, Pittman KA (1993) Effect of food on the bioavailability of gepirone in humans. J Clin Pharmacol 33:631-635
18. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI (1994) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitior antidepressants, and by quinidine and ketoconazole: a model system to predict drug interaction in vivo. J Pharmacol Exp Ther 268:1278-1283
19. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI (1995) Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 29 [suppl 1]33-43
20. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI (1996) Phenacetin O-deethylation by human liver microsomes in vitro: A inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology 125:398-407
21. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI (1998a) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38: 106-111
22. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI (1998b) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122
23. 1A agonists measured with the forced swim test. Psychopharmacology 101:497-504
24. Wilcox CS, Ferguson JM, Dale JL, Heiser JF (1996) A double-blind trial of low- and high-dose ranges of gepirone-ER compared with the placebo in the treatment of depressed outpatients. Psychopharmacol Bull 3:335-342